Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2019

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Datamonitor Healthcare

Reimbursement and Payer Management of Immune Checkpoint Inhibitors

21 Aug 2019

As immune checkpoint inhibitors continue to gain approvals in expanded patient populations, payers express concern surrounding the potential budget impact of the drug class. Considering the high costs of these treatments in comparison to standard chemotherapy, HTA and reimbursement agencies stress the requirement for solid survival data and highlight that price will be a major factor during negotiations

Topic Drug review

Single report
Datamonitor Healthcare

NASH Disease Coverage Extract

16 Aug 2019

Datamonitor Healthcare recently surveyed 60 gastroenterologists in the US and five major EU markets after the approval of the first disease-specific therapies for the treatment of non-alcoholic steatohepatitis (NASH). The market for these treatments will exceed $21bn in 2027.

Topic Drug development landscape Diseases

Single report
Scrip

An AdComm After All: Amarin's Vascepa Labeling Update Now Delayed By FDA

By Mandy Jackson 15 Aug 2019

The US FDA informed the company it will convene an advisory committee meeting to review the REDUCE-IT sNDA for the proprietary fish oil pill, delaying the approval by at least three months and surprising investors.

Topic FDA Drug approval

View article
Scrip

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

By Jessica Merrill 15 Aug 2019

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12 weeks in a head-to-head trial.

Topic Clinical trials

View article
Scrip

Oncology Market Leaders Maintain Their Upper Hand

By Jessica Merrill 14 Aug 2019

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.

Topic Drug development landscape Drug review

View article
Scrip

The Chinese Pharma Market: Insights in turbulent times

12 Aug 2019

With the continuation of the US-China trade standoff, the rapid increase in R&D costs and a gruelling centralized bidding process, foreign pharma firms have a lot on their plates in China. Gain insight on these key challenges through this Scrip article pack

Topic Business strategies

Single report
Trialtrove

Trialtrove 2018 Completed Clinical Trials Snapshot

12 Aug 2019

Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.

Topic Clinical trials Drug development landscape

Single report
Trialtrove

2018 Completed Trials: State of Industry-Sponsored Clinical Development

06 Aug 2019

The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.

Topic Drug development landscape

Single report
Scrip

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

By Brian Yang 05 Aug 2019

Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.

Topic Company analysis Business strategies

View article
Scrip

At Pfizer, A Split A Decade In The Making

By Jessica Merrill 05 Aug 2019

Pfizer's ambitious plans to spin out its Upjohn branded and generics business will result in a smaller, innovation-focused pharma. The decision comes after nine years of back-and-forth about whether the move would unlock value.

Topic BioPharmaceutical Company analysis

View article
Scrip

A New Day Dawns For Avastin

By Jessica Merrill 30 Jul 2019

The launch of Mvasi will be the first biosimilar version of Avastin in the US, a huge blockbuster for Roche approved for multiple cancer indications. Scrip looks at the development and commercial history of Avastin since its FDA approval in 2004.

Topic BioPharmaceutical Company analysis

View article
Scrip

Sunset Begins For Roche's Herceptin As Amgen/Allergan Biosimilar Launches

By Jessica Merrill 30 Jul 2019

Amgen and Allergan launched the first US biosimilar for Roche's Herceptin – and the Swiss pharma's Avastin – at a 15% discount to the brand-name products' list prices. Scrip's infographic reviews Herceptin's past and its future competitors.

Topic Biosimilars

View article
Biomedtracker

Biomedtracker Q3 2019 Outlook Report Extract

29 Jul 2019

In this report, we cover catalysts from 27 drugs, devices and diagnostics expected to occur in Q3 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

Topic Drug development landscape Drug review Research Strategy

Single report
Scrip, In Vivo

AI in the Pharmaceutical Landscape

25 Jul 2019

AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

Topic Digital Health Strategy Medtech

Single report
Scrip

Real-World Reluctance? Despite Guidance, Drug Developers Wary Of RWE-Based Trials

By Mandy Jackson 22 Jul 2019

Biopharma companies are reluctant to rely on real-world evidence trials, but while uncertainty remains about how these novel studies will be accepted, US and other regulators are encouraging drug developers to take a chance – and some have taken on the challenge.

Topic Policy and regulation

View article

Latest headlines

Scrip

23 Aug 2019

DREAMM-2 Put GSK’s BCMA Drug In Pole Position In Multiple Myeloma

Link
Scrip

23 Aug 2019

Lupin Rationalizes Japan Operations, Sheds Injectables Business

Link
Scrip

23 Aug 2019

Deal Watch: Themis Leverages Measles Vector Platform In Collaboration With Merck & Co.

Link
Scrip

23 Aug 2019

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Link
Scrip

22 Aug 2019

Longer Intervals OK With ViiV's Injectable Anti-HIV Regimen

Link
Scrip

22 Aug 2019

Executives On The Move: Top Hires At Ribon And SQZ And Roche Promotes A Business Leader

Link
Scrip

22 Aug 2019

Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

Link
Scrip

22 Aug 2019

Finance Watch: Chinook Debuts With $65m For Precision Kidney Disease Medicines

Link
Scrip

22 Aug 2019

AstraZeneca Buys Priority Review Voucher With Two Big Filings On The Horizon

Link
Scrip

22 Aug 2019

NICE Head Sir Andrew Dillon To Stand Down

Link
Scrip

22 Aug 2019

Novo Nordisk's Ultra-Fast Acting Insulin Cleared For Pediatric Use In EU

Link
Scrip

21 Aug 2019

Bayer Says $7.6bn Farewell To Animal Health As It Sells Unit To Elanco

Link
Scrip

21 Aug 2019

AstraZeneca’s Imfinzi-Treme Checkpoint Inhibitor Combination Fails Again In NSCLC

Link
Scrip

21 Aug 2019

Big Pharma Nibbles As Turkey’s Localization Policy Yields Limited Results

Link
Scrip

21 Aug 2019

Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Get ahead with in-depth pharmaceutical competitive intelligence

​Master the marketplace

Relevant products

Below are the Product List

Datamonitor Healthcare: data analysis and insight

Scrip: industry news and insights

Biomedtracker: follow the drug development process

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store

Master the marketplace